Antimicrobial Activity of Ceragenins against Vancomycin-Susceptible and -Resistant Enterococcus spp.

被引:3
|
作者
Hacioglu, Mayram [1 ]
Yilmaz, Fatima Nur [1 ]
Oyardi, Ozlem [2 ]
Guzel, Cagla Bozkurt [1 ]
Inan, Nese [3 ]
Savage, Paul B. [4 ]
Dosler, Sibel [1 ]
机构
[1] Istanbul Univ, Fac Pharm, Dept Pharmaceut Microbiol, TR-34116 Istanbul, Turkiye
[2] Gazi Univ, Fac Pharm, Dept Pharmaceut Microbiol, TR-06330 Ankara, Turkiye
[3] Univ Hlth Sci Ankara, Dr Abdurrahman Yurtaslan Oncol Training & Res Hosp, Medical Microbiol Lab, TR-06200 Ankara, Turkiye
[4] Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA
关键词
Enterococcus spp; ceragenin; linezolid; minimum inhibitory concentration; microbroth checkerboard; Caenorhabditis elegans; DAPTOMYCIN; SYNERGY;
D O I
10.3390/ph16121643
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ceragenins (CSAs) are a new class of antimicrobial agents designed to mimic the activities of endogenous antimicrobial peptides. In this study, the antibacterial activities of various ceragenins (CSA-13, CSA-44, CSA-90, CSA-131, CSA-138, CSA-142, and CSA-192), linezolid, and daptomycin were assessed against 50 non-repeated Enterococcus spp. (17 of them vancomycin-resistant Enterococcus-VRE) isolated from various clinical specimens. Among the ceragenins evaluated, the MIC50 and MIC90 values of CSA-44 and CSA-192 were the lowest (2 and 4 mu g/mL, respectively), and further studies were continued with these two ceragenins. Potential interactions between CSA-44 or CSA-192 and linezolid were tested and synergistic interactions were seen with the CSA-192-linezolid combination against three Enterococcus spp., one of them VRE. The effects of CSA-44 and CSA-192 on the MIC values of vancomycin were also investigated, and the largest MIC change was seen in the vancomycin-CSA-192 combination. The in vivo effects of CSA-44 and CSA-192 were evaluated in a Caenorhabditis elegans model system. Compared to no treatment, increased survival was observed with C. elegans when treated with ceragenins. In conclusion, CSA-44 and CSA-192 appear to be good candidates (alone or in combination) for the treatment of enterococcal infections, including those from VRE.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Activity of serum concentrations of daptomycin vs. vancomycin against vancomycin-susceptible and resistant Enterococcus faecium in the presence of albumin physiological concentrations:: an in vitro pharmacodynamic simulation
    Alou, L.
    Aguilar, L.
    Gimenez, M. J.
    Torrico, M.
    Sevillano, D.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2008, 27 (10) : 1009 - 1011
  • [22] Comparative evaluation of penicillin, ampicillin, and imipenem MICs and susceptibility breakpoints for vancomycin-susceptible and vancomycin-resistant Enterococcus faecalis and Enterococcus faecium
    Weinstein, MP
    JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (07) : 2729 - 2731
  • [23] A Report of Vancomycin-susceptible, Teicoplanin-resistant Enterococcus faecalis ST6 in Malaysia
    Loong, S. K.
    Seri, Che Mat N. A. A.
    Mahfodz, N. H.
    Nasrah, Ahmad S. N.
    Akbar, S. Z.
    AbuBakar, S.
    TROPICAL BIOMEDICINE, 2016, 33 (03) : 577 - 582
  • [24] Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains
    Zelenitsky, SA
    Karlowsky, JA
    Zhanel, GG
    Hoban, DJ
    Nicas, T
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) : 1407 - 1408
  • [25] Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E-faecium
    Linden, PK
    Pasculle, AW
    Manez, R
    Kramer, DJ
    Fung, JJ
    Pinna, AD
    Kusne, S
    CLINICAL INFECTIOUS DISEASES, 1996, 22 (04) : 663 - 670
  • [26] Survival of vancomycin-resistant and vancomycin-susceptible enterococci on dry surfaces
    Wendt, C
    Wiesenthal, B
    Dietz, E
    Ruden, H
    JOURNAL OF CLINICAL MICROBIOLOGY, 1998, 36 (12) : 3734 - 3736
  • [27] Emergence of vancomycin-resistant enterococci from vancomycin-susceptible enterococci in hospitalized patients under antimicrobial therapy
    Janice, Jessin
    Wagner, Theresa Maria
    Olsen, Karina
    Hegstad, Joachim
    Hegstad, Kristin
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2024, 36 : 116 - 122
  • [28] Vancomycin-Variable Enterococcus faecium: In Vivo Emergence of Vancomycin Resistance in a Vancomycin-Susceptible Isolate
    Coburn, Bryan
    Low, Donald E.
    Patel, Samir N.
    Poutanen, Susan M.
    Shahinas, Dea
    Eshaghi, Alireza
    Willey, Barbara M.
    McGeer, Allison
    JOURNAL OF CLINICAL MICROBIOLOGY, 2014, 52 (05) : 1766 - 1767
  • [29] Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin
    Rathe, Mathias
    Kristensen, Lise
    Ellermann-Eriksen, Svend
    Thomsen, Marianne Kragh
    Schumacher, Helga
    APMIS, 2010, 118 (01) : 66 - 73
  • [30] Identification of vancomycin-susceptible major clones of clinical Enterococcus from Algeria
    Bourafa, Nadjette
    Abat, Cedric
    Loucif, Lotfi
    Olaitan, Abiola Olumuyiwa
    Bentorki, Ahmed Aimen
    Boutefnouchet, Nafissa
    Rolain, Jean-Marc
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2016, 6 : 78 - 83